The U.S. drug-coated balloon market just became competitive. Medtronic PLC announced FDA approval of its IN.PACT Admiral paclitaxel-coated balloon for treating peripheral artery disease Jan. 5, primed for a match up with CR Bard Inc.'s first-to-market Lutonix 035.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?